01/03/2026
Precision That Drives Clinical Excellence & Economic Stability
In prostate cancer care, hospitals face dual pressure:
Deliver better outcomes. Maintain financial sustainability.
The ExactVu™ 29 MHz Micro-Ultrasound bridges that gap.
🔬 Detects more clinically significant prostate cancer (csPCa) missed by conventional ultrasound — with real-time targeted biopsy.
🧠 Beyond diagnosis: Ideal for Active Surveillance, re-biopsy, post-therapy evaluation, and precision treatment planning.
📊 High detection — with or without MRI, expanding access and reducing diagnostic delays.
💰 Reduced MRI dependency = Lower costs, faster turnaround, higher efficiency.
🔎 29 MHz visualization delivers near-pathological tissue detail — transforming blind biopsy into precision targeting.
⸻
Clinical Superiority. Economic Sustainability. Strategic Advantage.